What's the difference between Retatrutide and Tirzepatide?
Retatrutide is a metabolic & weight loss that retatrutide is a 39-amino-acid synthetic peptide with balanced agonist activity at three receptors: glp-1r, gipr, and gcgr (glucagon receptor). it is chemically modified with a c20…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (~6 days (plasma, albumin-bound) vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range.
Which has the longer half-life, Retatrutide or Tirzepatide?
Retatrutide has a half-life of ~6 days (plasma, albumin-bound). Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, Retatrutide or Tirzepatide?
Lowest listed price on BodyHackGuide: Retatrutide from $79.99, Tirzepatide from $49.00. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack Retatrutide and Tirzepatide?
Stacking depends on mechanism overlap, safety profile, and goals. Retatrutide and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
Is retatrutide stronger than tirzepatide?
At their highest published doses (retatrutide 12 mg weekly vs tirzepatide 15 mg weekly), retatrutide produced 24.2% body-weight loss at 48 weeks in Phase 2, vs tirzepatide's 22.5% at 72 weeks in SURMOUNT-1. Retatrutide's curve was still descending at trial end, so the gap likely widens with longer follow-up. The 'stronger' framing assumes you tolerate the higher dose: both require slow titration to manage GI side effects.
Can you switch from tirzepatide to retatrutide?
Most users cross-titrate over 2-4 weeks: hold the last tirzepatide dose, then start retatrutide at 2-4 mg weekly and escalate from there. Direct dose-matching doesn't work cleanly because the receptor profiles differ: retatrutide's glucagon arm changes satiety + metabolic dynamics. Track resting heart rate during the switch (retatrutide raises it) and watch for GI re-flare during the first 2-3 weeks at any new dose.
Will retatrutide get FDA approval?
The main Phase 3 obesity results are in. TRIUMPH-1 reported 28.3% average weight loss at 80 weeks on the 12 mg dose (May 2026), and TRIUMPH-2 and TRIUMPH-3 met their primary endpoints (July 2026). Eli Lilly has signaled retatrutide as the successor to tirzepatide in their obesity pipeline and plans to submit it to the FDA in Q1 2027. An obesity approval would come after the FDA reviews it.
Which has fewer side effects, retatrutide or tirzepatide?
Front-end GI profiles are nearly identical (nausea 40-60%, vomiting 15-25%, diarrhea 15-30%). Tirzepatide has the longer post-market safety record (FDA-approved 2022). Both raise heart rate; retatrutide's rise peaked at 24 weeks in Phase 2 and declined after that, at a size its trial authors called similar to GLP-1 receptor agonists, and the trial showed no hepatotoxicity signal through 48 weeks. Tirzepatide carries the GLP-1 class boxed warning for thyroid C-cell tumors; retatrutide has no FDA label yet.
How much weight will I lose on retatrutide vs tirzepatide?
Trial means: tirzepatide at 15 mg = ~22.5% body weight at 72 weeks. Retatrutide at 12 mg = ~24.2% at 48 weeks. Individual response varies widely: at 48 weeks in the 12 mg group, 83% lost at least 15% of body weight and 26% lost 30% or more. Plan for a slower titration (2.5-4 mg/month dose increases).
Can you stack retatrutide and tirzepatide?
No, they hit overlapping receptors (GLP-1 + GIP) and stacking would compound side effects without proportional efficacy gain. The published research on both is monotherapy. If you want triple-agonist coverage, retatrutide alone provides it. If you want dual agonist with pharmacy access, tirzepatide alone is the answer. Pick one.
How do I switch from tirzepatide to retatrutide?
The standard cross-titration is a 2-3 week hold on tirzepatide (let receptor saturation drop), then start retatrutide at 2-4 mg/wk and escalate +2 mg every 4 weeks to 8-12 mg maintenance. Expect a controlled GI re-flare during week 1-2 of retatrutide. Track CMP + resting heart rate during titration (retatrutide raises heart rate). Full step-by-step protocol at /blog/tirzepatide-to-retatrutide-switch-protocol.